How to Select Patients for Psilocybin in Chronic Suicidal Ideation
How do clinicians identify which patients with major depressive disorder and chronic suicidal ideation fit the study-supported psilocybin treatment population?
Patients with chronic suicidal ideation often remain symptomatic despite multiple adequate antidepressant trials, yet most psychedelic studies have excluded them. This guide applies to the narrow population actually studied: adults with major depressive disorder, chronic suicidal ideation, and treatment resistance, but without recent imminent suicidal intent or key contraindications used in prior psychedelic research.
-
Confirm major depressive disorder and treatment resistance
Verify that the patient is an adult aged 18 to 65 years with DSM-5 major depressive disorder. The study required insufficient response to at least 2 adequate antidepressant trials, so the workflow applies only to patients with treatment-resistant depression by that definition.
-
Establish chronic suicidal ideation severity and duration
Confirm chronic suicidal ideation as active suicidal thoughts on more days than not for at least 3 months, with each episode lasting at least 1 hour. Also confirm Columbia-Suicide Severity Rating Scale scores of 3 or 4 within the past year at both screening and baseline, because that was the suicidality threshold required for enrollment.
-
Exclude recent imminent suicide risk
Do not treat this protocol as matching patients who have had a C-SSRS score of 5, defined in the article as active plan and imminent intent, within the preceding 3 months. The study specifically excluded those individuals in order to target sustained suicidal ideation without acute risk.
-
Screen for psychiatric and medical exclusions
Exclude patients with a personal or first-degree family history of psychotic disorder or bipolar I disorder. Also exclude active substance use disorder within 12 months and unstable medical conditions that would contraindicate psilocybin administration, because these were part of the study exclusion framework.
-
Complete medication taper and washout before dosing
Before psilocybin administration, complete a supervised taper and washout of all psychotropic medications for at least 2 weeks or 5 half-lives, whichever is longer. This was part of the intervention as delivered in the study and defines the treatment context in which outcomes were observed.
-
Provide the structured psychological support model
Match the intervention to the study format by using 3 preparatory sessions totaling at least 6 hours with 2 trained therapists, focused on rapport building, psychoeducation, and intention setting. Administer a single oral 25-mg psilocybin dose in a dedicated room designed for comfort and psychological safety, with therapists present throughout an approximately 8-hour session, followed by 3 integration meetings beginning the next day and continuing over subsequent weeks.
Clinical Considerations
- This population excluded patients with recent active plan and imminent intent, so the findings do not apply to acutely suicidal patients at immediate risk.
- The study was open-label, single-arm, and conducted at a specialized academic center with highly trained therapists, which limits generalizability to routine practice settings.
- Because the intervention included medication washout plus structured preparation, dosing, and integration, the observed outcomes should not be attributed to psilocybin in isolation.
- Exploratory findings suggested that stronger baseline hopelessness and pessimism were associated with nonresponse, but these signals were hypothesis-generating only.
Bottom Line
Use this study only for carefully screened adults with major depressive disorder, chronic but nonimminent suicidal ideation, treatment resistance, psychotropic washout, and a full structured psilocybin-assisted therapy framework.
